TherapeuticsMD, Inc. (TXMD)
USD 1.03
(4.06%)
USD 1.03
(4.06%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -8.52 Million USD | -142.33% |
| 2022 | 20.13 Million USD | 114.41% |
| 2021 | -139.77 Million USD | 10.14% |
| 2020 | -155.54 Million USD | -2.87% |
| 2019 | -151.2 Million USD | -16.12% |
| 2018 | -130.22 Million USD | -67.75% |
| 2017 | -77.62 Million USD | 13.99% |
| 2016 | -90.25 Million USD | -5.94% |
| 2015 | -85.19 Million USD | -57.64% |
| 2014 | -54.04 Million USD | -109.39% |
| 2013 | -25.8 Million USD | -59.82% |
| 2012 | -16.14 Million USD | -197.55% |
| 2011 | -5.42 Million USD | -1059.76% |
| 2010 | -467.95 Thousand USD | 71.56% |
| 2009 | -1.64 Million USD | -316.05% |
| 2008 | -395.55 Thousand USD | -321.95% |
| 2007 | -93.74 Thousand USD | -119.17% |
| 2006 | 488.88 Thousand USD | 40.08% |
| 2005 | 348.99 Thousand USD | 77.37% |
| 2004 | 196.75 Thousand USD | 88.99% |
| 2003 | 104.1 Thousand USD | 5.25% |
| 2002 | 98.91 Thousand USD | 60.74% |
| 2001 | 61.53 Thousand USD | -53.27% |
| 2000 | 131.66 Thousand USD | 741.65% |
| 1999 | 15.64 Thousand USD | 423.42% |
| 1998 | -4837.00 USD | -109.82% |
| 1997 | 49.26 Thousand USD | -33.84% |
| 1996 | 74.46 Thousand USD | 106.25% |
| 1995 | 36.1 Thousand USD | 5.62% |
| 1994 | 34.18 Thousand USD | -19.72% |
| 1993 | 42.57 Thousand USD | 0.0% |
| 1992 | - USD | 0.0% |
| 1991 | - USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -1.14 Million USD | 29.11% |
| 2024 Q2 | -1.17 Million USD | -113.66% |
| 2023 Q2 | -2.47 Million USD | 7.31% |
| 2023 Q3 | -1.77 Million USD | 28.28% |
| 2023 Q4 | -1.61 Million USD | 9.14% |
| 2023 Q1 | -2.66 Million USD | -102.39% |
| 2023 FY | -8.52 Million USD | -142.33% |
| 2022 FY | 20.13 Million USD | 114.41% |
| 2022 Q4 | 111.57 Million USD | 637.8% |
| 2022 Q3 | -20.74 Million USD | -10.12% |
| 2022 Q1 | -26.22 Million USD | 25.89% |
| 2022 Q2 | -18.84 Million USD | 28.17% |
| 2021 Q3 | -39.92 Million USD | -13.48% |
| 2021 Q2 | -35.17 Million USD | -20.16% |
| 2021 Q1 | -29.27 Million USD | 15.4% |
| 2021 Q4 | -35.39 Million USD | 11.34% |
| 2021 FY | -139.77 Million USD | 10.14% |
| 2020 FY | -155.54 Million USD | -2.87% |
| 2020 Q1 | -50.92 Million USD | -14.71% |
| 2020 Q2 | -45.03 Million USD | 11.55% |
| 2020 Q3 | -24.97 Million USD | 44.55% |
| 2020 Q4 | -34.6 Million USD | -38.58% |
| 2019 Q1 | -38.1 Million USD | 0.04% |
| 2019 Q3 | -27.07 Million USD | 34.98% |
| 2019 FY | -151.2 Million USD | -16.12% |
| 2019 Q2 | -41.63 Million USD | -9.27% |
| 2019 Q4 | -44.39 Million USD | -63.98% |
| 2018 Q4 | -38.12 Million USD | -10.94% |
| 2018 Q2 | -33.02 Million USD | -33.6% |
| 2018 Q1 | -24.71 Million USD | -14.0% |
| 2018 Q3 | -34.36 Million USD | -4.06% |
| 2018 FY | -130.22 Million USD | -67.75% |
| 2017 Q2 | -19.82 Million USD | 6.84% |
| 2017 FY | -77.62 Million USD | 13.99% |
| 2017 Q4 | -21.68 Million USD | -46.18% |
| 2017 Q3 | -14.83 Million USD | 25.2% |
| 2017 Q1 | -21.28 Million USD | 7.21% |
| 2016 Q1 | -20.97 Million USD | -19.79% |
| 2016 Q2 | -21.21 Million USD | -1.13% |
| 2016 Q3 | -25.12 Million USD | -18.47% |
| 2016 Q4 | -22.94 Million USD | 8.7% |
| 2016 FY | -90.25 Million USD | -5.94% |
| 2015 Q2 | -27.25 Million USD | -30.27% |
| 2015 FY | -85.19 Million USD | -57.64% |
| 2015 Q4 | -17.5 Million USD | 10.22% |
| 2015 Q3 | -19.5 Million USD | 28.44% |
| 2015 Q1 | -20.92 Million USD | -28.24% |
| 2014 FY | -54.04 Million USD | -109.39% |
| 2014 Q2 | -10.92 Million USD | -22.08% |
| 2014 Q3 | -17.84 Million USD | -63.34% |
| 2014 Q1 | -8.95 Million USD | -11.73% |
| 2014 Q4 | -16.31 Million USD | 8.59% |
| 2013 FY | -25.8 Million USD | -59.82% |
| 2013 Q4 | -8.01 Million USD | -10.7% |
| 2013 Q3 | -7.23 Million USD | -28.84% |
| 2013 Q2 | -5.61 Million USD | -13.64% |
| 2013 Q1 | -4.94 Million USD | 8.38% |
| 2012 Q3 | -3.91 Million USD | 1.61% |
| 2012 Q4 | -5.39 Million USD | -37.96% |
| 2012 Q2 | -3.97 Million USD | -38.58% |
| 2012 Q1 | -2.86 Million USD | 45.52% |
| 2012 FY | -16.14 Million USD | -197.55% |
| 2011 Q3 | -62.49 Thousand USD | -6.64% |
| 2011 FY | -5.42 Million USD | -1059.76% |
| 2011 Q1 | -41.73 Thousand USD | 68.14% |
| 2011 Q2 | -58.6 Thousand USD | -40.41% |
| 2011 Q4 | -5.26 Million USD | -8323.82% |
| 2010 Q2 | -84.27 Thousand USD | 75.13% |
| 2010 Q4 | -130.98 Thousand USD | -6.77% |
| 2010 Q3 | -122.68 Thousand USD | -45.57% |
| 2010 Q1 | -338.86 Thousand USD | 45.85% |
| 2010 FY | -467.95 Thousand USD | 71.56% |
| 2009 Q2 | -14.16 Thousand USD | 51.2% |
| 2009 FY | -1.64 Million USD | -316.05% |
| 2009 Q3 | -488.34 Thousand USD | -3346.57% |
| 2009 Q4 | -625.78 Thousand USD | -28.14% |
| 2009 Q1 | -29.03 Thousand USD | -242.65% |
| 2008 Q1 | -35.12 Thousand USD | 89.94% |
| 2008 FY | -395.55 Thousand USD | -321.95% |
| 2008 Q3 | -46.5 Thousand USD | 84.78% |
| 2008 Q2 | -305.45 Thousand USD | -769.69% |
| 2008 Q4 | -8473.00 USD | 81.78% |
| 2007 Q3 | 105.48 Thousand USD | 8.12% |
| 2007 FY | -93.74 Thousand USD | -119.17% |
| 2007 Q4 | -349.08 Thousand USD | -430.93% |
| 2007 Q2 | 97.56 Thousand USD | 24.45% |
| 2007 Q1 | 78.39 Thousand USD | -5.78% |
| 2006 Q1 | 73.8 Thousand USD | -30.49% |
| 2006 Q3 | 227.62 Thousand USD | 138.19% |
| 2006 FY | 488.88 Thousand USD | 40.08% |
| 2006 Q4 | 83.2 Thousand USD | -63.45% |
| 2006 Q2 | 95.56 Thousand USD | 29.48% |
| 2005 Q1 | 84 Thousand USD | -4.74% |
| 2005 Q2 | 17.35 Thousand USD | -79.34% |
| 2005 FY | 348.99 Thousand USD | 77.37% |
| 2005 Q3 | 141.45 Thousand USD | 715.06% |
| 2005 Q4 | 106.18 Thousand USD | -24.94% |
| 2004 Q4 | 88.18 Thousand USD | 44.67% |
| 2004 Q1 | 33.86 Thousand USD | 4.23% |
| 2004 Q2 | 22.23 Thousand USD | -34.34% |
| 2004 Q3 | 60.95 Thousand USD | 174.13% |
| 2004 FY | 196.75 Thousand USD | 88.99% |
| 2003 Q2 | 14.34 Thousand USD | 9.91% |
| 2003 FY | 104.1 Thousand USD | 5.25% |
| 2003 Q4 | 32.48 Thousand USD | -26.54% |
| 2003 Q3 | 44.22 Thousand USD | 208.3% |
| 2003 Q1 | 13.05 Thousand USD | -63.8% |
| 2002 Q4 | 36.05 Thousand USD | 53.98% |
| 2002 Q1 | 22.81 Thousand USD | 201.79% |
| 2002 Q2 | 16.62 Thousand USD | -27.15% |
| 2002 FY | 98.91 Thousand USD | 60.74% |
| 2002 Q3 | 23.41 Thousand USD | 40.87% |
| 2001 Q2 | 32.03 Thousand USD | -18.46% |
| 2001 Q1 | 39.29 Thousand USD | -43.01% |
| 2001 FY | 61.53 Thousand USD | -53.27% |
| 2001 Q4 | -22.41 Thousand USD | -277.65% |
| 2001 Q3 | 12.61 Thousand USD | -60.62% |
| 2000 Q3 | 36.75 Thousand USD | 144.45% |
| 2000 Q2 | 15.03 Thousand USD | 37.55% |
| 2000 Q1 | 10.93 Thousand USD | 662.74% |
| 2000 FY | 131.66 Thousand USD | 741.65% |
| 2000 Q4 | 68.95 Thousand USD | 87.63% |
| 1999 Q1 | -7433.00 USD | 0.0% |
| 1999 Q3 | 11.83 Thousand USD | 25.8% |
| 1999 Q2 | 9410.00 USD | 226.6% |
| 1999 FY | 15.64 Thousand USD | 423.42% |
| 1999 Q4 | 1433.00 USD | -87.89% |
| 1998 FY | -4837.00 USD | -109.82% |
| 1997 FY | 49.26 Thousand USD | -33.84% |
| 1996 FY | 74.46 Thousand USD | 106.25% |
| 1995 FY | 36.1 Thousand USD | 5.62% |
| 1994 FY | 34.18 Thousand USD | -19.72% |
| 1993 FY | 42.57 Thousand USD | 0.0% |
| 1992 FY | - USD | 0.0% |
| 1991 FY | - USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 166.96 Million USD | 105.105% |
| Embecta Corp. | 221.5 Million USD | 103.848% |
| ANI Pharmaceuticals, Inc. | 46.97 Million USD | 118.145% |
| Dynavax Technologies Corporation | -37.02 Million USD | 76.982% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | 94.521% |
| Pacira BioSciences, Inc. | 87.67 Million USD | 109.721% |
| PainReform Ltd. | -9.58 Million USD | 11.071% |
| Aquestive Therapeutics, Inc. | -15.1 Million USD | 43.564% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | -78.108% |
| SCYNEXIS, Inc. | 72.66 Million USD | 111.729% |
| China SXT Pharmaceuticals, Inc. | -2.51 Million USD | -238.857% |
| Cosmos Health Inc. | -21.83 Million USD | 60.96% |
| Journey Medical Corporation | -2.07 Million USD | -311.143% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | -78.108% |
| Safety Shot Inc | -12.18 Million USD | 30.048% |
| Alpha Teknova, Inc. | -35.56 Million USD | 76.034% |
| Intra-Cellular Therapies, Inc. | -159.38 Million USD | 94.652% |
| Bright Green Corporation | -8.89 Million USD | 4.143% |
| Procaps Group, S.A. | 38.97 Million USD | 121.869% |
| Theratechnologies Inc. | -10.62 Million USD | 19.799% |
| Harrow Health, Inc. | 580 Thousand USD | 1569.483% |
| Sonoma Pharmaceuticals, Inc. | -4.7 Million USD | -81.302% |
| Biofrontera Inc. | -22.67 Million USD | 62.416% |
| DURECT Corporation | -36.88 Million USD | 76.892% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | -61.757% |
| Cronos Group Inc. | -81.37 Million USD | 89.526% |
| OptiNose, Inc. | -22.74 Million USD | 62.533% |
| Ironwood Pharmaceuticals, Inc. | 209.03 Million USD | 104.077% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | 78.232% |
| RedHill Biopharma Ltd. | 12.63 Million USD | 167.472% |
| Organogenesis Holdings Inc. | 12.52 Million USD | 168.048% |
| Guardion Health Sciences, Inc. | -4.33 Million USD | -96.549% |
| Cumberland Pharmaceuticals Inc. | -6.21 Million USD | -37.228% |
| Radius Health, Inc. | -3.92 Million USD | -117.146% |
| Universe Pharmaceuticals INC | -3.52 Million USD | -141.666% |
| ProPhase Labs, Inc. | -21.61 Million USD | 60.565% |
| Phibro Animal Health Corporation | 53.31 Million USD | 115.986% |
| Procaps Group S.A. | 52.32 Million USD | 116.289% |
| Alvotech | -354.86 Million USD | 97.598% |
| Viatris Inc. | 766.2 Million USD | 101.112% |
| Rockwell Medical, Inc. | -6.67 Million USD | -27.781% |
| Aytu BioPharma, Inc. | -5.25 Million USD | -62.219% |
| SIGA Technologies, Inc. | 83.62 Million USD | 110.192% |
| Tilray Brands, Inc. | -174.74 Million USD | 95.123% |
| Lifecore Biomedical, Inc. | 9.33 Million USD | 191.341% |
| Shineco, Inc. | -17.06 Million USD | 50.058% |
| PetIQ, Inc. | 60.01 Million USD | 114.201% |
| Regencell Bioscience Holdings Limited | -4.73 Million USD | -79.934% |
| Incannex Healthcare Limited | -30.04 Million USD | 71.629% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 103.397% |
| Alimera Sciences, Inc. | -1.47 Million USD | -479.402% |
| Silver Spike Investment Corp. | 7.34 Million USD | 216.115% |
| Assertio Holdings, Inc. | -243.53 Million USD | 96.5% |
| Shuttle Pharmaceuticals Holdings, Inc. | -5.89 Million USD | -44.644% |
| Petros Pharmaceuticals, Inc. | -13.61 Million USD | 37.411% |
| Clever Leaves Holdings Inc. | -15.59 Million USD | 45.344% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 57.491% |
| Avadel Pharmaceuticals plc | -137.84 Million USD | 93.817% |
| Hempacco Co., Inc. | -8.81 Million USD | 3.283% |
| Talphera, Inc. | -16.88 Million USD | 49.535% |
| Alvotech | -354.86 Million USD | 97.598% |
| Eagle Pharmaceuticals, Inc. | 53.45 Million USD | 115.945% |
| Lantheus Holdings, Inc. | 364.64 Million USD | 102.337% |
| Currenc Group, Inc. | -6.64 Million USD | -28.247% |
| Kamada Ltd. | 10.06 Million USD | 184.688% |
| Indivior PLC | -4 Million USD | -113.075% |
| Evoke Pharma, Inc. | -7.43 Million USD | -14.697% |
| Flora Growth Corp. | -50.35 Million USD | 83.074% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 57.491% |
| Evolus, Inc. | -49.23 Million USD | 82.688% |
| HUTCHMED (China) Limited | 18.37 Million USD | 146.384% |
| Amphastar Pharmaceuticals, Inc. | 196.98 Million USD | 104.327% |
| Akanda Corp. | -10.05 Million USD | 15.206% |